Heparin (Low Molecular Weight)

Name
Heparin (Low Molecular Weight)
Accession Number
DBCAT002680  (DBCAT001306)
Description

Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.

Drugs
DrugDrug Description
BemiparinAn ultra-low molecular weight heparin (ultra-LMWH) used to prevent thromboembolism following surgery and extracorporeal clotting during dialysis.
NadroparinA low molecular weight heparin used for the prophylaxis of thrombotic events and deep vein thrombosis, and prevent unstable angina and non-Q-wave myocardial infarction.
ReviparinBy the FDA, reviparin is indicated for the treatment of deep vein which may lead to pulmonary embolism in pediatric patients. It is also indicated for the long-term treatment of...
TinzaparinA low molecular weight heparin used for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin.
EnoxaparinA low molecular weight heparin used for the prophylaxis of deep vein thrombosis and ischemic complications of unstable angina and non-Q-wave myocardial infarction.
ParnaparinA low molecular weight heparin (LMWH) used to prevent blood clots, specifically deep vein thrombosis.
CertoparinA low molecular weight heparin (LMWH) used to prevent blood clots, specifically deep vein thrombosis.
DalteparinA low molecular weight heparin used for the prophylaxis of thrombotic events in certain patients and prevent acute cardiac ischemic events in patients with unstable angina and non-Q-wave myocardial infarction.
ArdeparinFor prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.
Cinnamic acidNot Annotated
Drugs & Drug Targets
DrugTargetType
BemiparinCoagulation factor Xtarget
BemiparinAntithrombin-IIItarget
BemiparinHeparin cofactor 2target
NadroparinProto-oncogene c-Fostarget
NadroparinMyc proto-oncogene proteintarget
NadroparinP-selectintarget
NadroparinAntithrombin-IIItarget
TinzaparinAntithrombin-IIItarget
TinzaparinA disintegrin and metalloproteinase with thrombospondin motifs 4enzyme
TinzaparinIntegrin alpha-4target
TinzaparinStromal cell-derived factor 1target
EnoxaparinAntithrombin-IIItarget
EnoxaparinCoagulation factor Xtarget
EnoxaparinMyeloperoxidaseenzyme
EnoxaparinProthrombintarget
DalteparinVascular endothelial growth factor Atarget
DalteparinHeparanaseenzyme
DalteparinAntithrombin-IIItarget
DalteparinP-selectintarget
ArdeparinHeparin cofactor 2target
ArdeparinAntithrombin-IIItarget